Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Devimistat with Cytarabine and Mitoxantrone in Relapsed/Refractory AML
NCT02484391Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Sep 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of devimistat in acute myeloid leukemia (AML) and granulocytic sarcoma (MS), sponsored by Wake Forest University Health Sciences. Primary endpoint: Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone up to 12 weeks. Started Sep 2015; status: completed.
02
Drugs
devimistat
03
Conditions
acute myeloid leukemia (AML)granulocytic sarcoma (MS)
Beyond the preview
Go deeper on NCT02484391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484391.